![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Consonance HFW Acquisition Corp | AMEX:CHFW | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.79 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
Surrozen, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
86889P109
(CUSIP NUMBER)
Kevin Livingston
1370 Avenue of the Americas, 33rd Floor
New York, NY 10019
(212) 660-8060
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
December 12, 2022
(Date of event which requires filing of this statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box ☐.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the Act), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
CUSIP No. 86889P109 NAME OF REPORTING PERSONS Consonance Capital Management LP CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP* (a) ☐ (b) ☐ SEC USE ONLY SOURCE OF FUNDS* AF CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ CITIZENSHIP OR PLACE OF
ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 0 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11) 0% TYPE OF REPORTING
PERSON* IA, PN SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 86889P109 NAME OF REPORTING PERSONS Consonance Capman GP LLC CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP* (a) ☐ (b) ☐ SEC USE ONLY SOURCE OF FUNDS* AF CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ CITIZENSHIP OR PLACE OF
ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 0 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11) 0% TYPE OF REPORTING
PERSON* HC, OO SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 86889P109 NAME OF REPORTING PERSONS Consonance Life Sciences, LLC CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP* (a) ☐ (b) ☐ SEC USE ONLY SOURCE OF FUNDS* WC CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ CITIZENSHIP OR PLACE OF
ORGANIZATION Cayman
Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 0 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11) 0% TYPE OF REPORTING
PERSON* OO SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 86889P109 NAME OF REPORTING PERSONS Mitchell Blutt CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP* (a) ☐ (b) ☐ SEC USE ONLY SOURCE OF FUNDS* AF CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ CITIZENSHIP OR PLACE OF
ORGANIZATION United
States NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 0 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11) 0% TYPE OF REPORTING
PERSON* HC, IN SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 86889P109 NAME OF REPORTING PERSONS Benny Soffer CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP* (a) ☐ (b) ☐ SEC USE ONLY SOURCE OF FUNDS* AF CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ CITIZENSHIP OR PLACE OF
ORGANIZATION United
States NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 0 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11) 0% TYPE OF REPORTING
PERSON* IN SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 86889P109 NAME OF REPORTING PERSONS Kevin Livingston CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP* (a) ☐ (b) ☐ SEC USE ONLY SOURCE OF FUNDS* AF CHECK BOX IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☐ CITIZENSHIP OR PLACE OF
ORGANIZATION United
States NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 0 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11) 0% TYPE OF REPORTING
PERSON* IN * SEE INSTRUCTIONS BEFORE FILLING OUT
Amendment No. 4 to Schedule 13D The following constitutes Amendment No. 4 (Amendment No. 4) to the Schedule 13D filed with the Securities and Exchange Commission
(SEC) by Consonance Capital Management LP, a Delaware limited partnership (Consonance Management), Consonance Capital Opportunity Fund Management LP, a Delaware limited partnership (Consonance Opportunity),
Consonance Capman GP LLC, a Delaware limited liability company (Capman), Consonance Life Sciences, LLC, a Cayman Islands limited liability company (Consonance Life Sciences), Dr. Mitchell Blutt, Dr. Benny Soffer,
and Kevin Livingston (collectively, the Reporting Persons) on December 3, 2020, as amended by Amendment No. 1 filed on April 27, 2021, Amendment No. 2 filed on August 18, 2021, and Amendment No. 3 filed on
September 29, 2021. This Amendment No. 4 amends and supplements the Schedule 13D as specifically set forth herein. All capitalized terms
contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. This Schedule 13D relates to the Common Stock, par value $0.0001 per share (the Common Stock) and warrants to purchase shares of Common Stock of
Surrozen, Inc. (the Issuer) that were held by certain private investment funds, including Consonance Capital Master Account LP (the Master Account) and Consonance Capital Opportunity Master Fund, LP (Consonance
Opportunity Master) and a certain managed account (the Managed Account, and together with the Master Account and Consonance Opportunity Master, the Consonance Investors) for which Consonance Management serves as
investment adviser. As the general partner of Consonance Management, Capman had the power to direct the vote and disposition of the securities of the Issuer that were held by the Consonance Investors. As principal of Consonance Management,
Dr. Blutt had the power to direct the vote and disposition of the securities of the Issuer that were held by the Consonance Investors. In addition, this Schedule 13D relates to Common Stock and warrants to purchase shares of Common Stock
that were held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Dr. Blutt, Dr. Soffer and Kevin Livingston. As such, Dr. Blutt, Dr. Soffer and Kevin Livingston may have
been deemed to have had voting and investment discretion over the securities of the Issuer that were held by Consonance Life Sciences. Purpose of Transaction Item 4 of the Schedule 13D is supplemented and superseded, as the case may be, as follows: On December 12, 2022, the Master Account, Consonance Opportunity Master, the Managed Account, Consonance Life Sciences, and the Issuer entered into a
Securities Purchase Agreement (the Purchase Agreement). Pursuant to the Purchase Agreement, Master Account agreed to sell to the Issuer 1,748,750 shares of Common Stock of the Issuer and warrants to purchase 582,916 shares of Common
Stock of the Issuer for an aggregate purchase price of $874,375. Pursuant to the Purchase Agreement, Consonance Opportunity Master agreed to sell to the Issuer 1,297,922 shares of Common Stock of the Issuer and warrants to purchase 432,639 shares of
Common Stock of the Issuer for an aggregate purchase price of $648,961. Pursuant to the Purchase Agreement, the Managed Account agreed to sell to the Issuer 450,827 shares of Common Stock of the
Issuer and warrants to purchase 150,275 shares of Common Stock of the Issuer for an aggregate purchase price of $225,413.50. Pursuant to the Purchase Agreement, Consonance Life Sciences agreed to sell to the Issuer 1,885,000 shares of Common Stock
of the Issuer and warrants to purchase 144,666 shares of Common Stock of the Issuer for an aggregate purchase price of $942,500. Each warrant entitles the holder thereof to purchase one share of Common Stock of the Issuer at a price of $11.50 per
share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation. The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the
Purchase Agreement, which is filed as Exhibit 99.1, and is incorporated herein by reference. Interest in Securities of the Issuer Item 5 of the Schedule 13D is hereby amended and restated as follows: (a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference. (c) The information in Item 4 is incorporated herein by reference. (d) The disclosure in Item 2 and Item 4 is incorporated herein by reference. (e) As of December 14, 2022, all of the Reporting Persons ceased to be the beneficial owner of more than five percent of any class of securities of the
Issuer. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Item 6 of the Schedule 13D is supplemented and superseded, as the case may be, as follows: The information in Item 4 is incorporated herein by reference. The Purchase Agreement is filed as Exhibit 99.1 to this Schedule 13D and is incorporated herein by reference. Material To Be Filed as Exhibit
Signatures After reasonable inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is
true, complete and correct. Dated: December 15, 2022 Mitchell Blutt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
*
1
2
3
4
5
6
7
8
9
10
11
12
13
14
*
1
2
3
4
5
6
7
8
9
10
11
12
13
14
*
1
2
3
4
5
6
7
8
9
10
11
12
13
14
*
1
2
3
4
5
6
7
8
9
10
11
12
13
14
*
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Item 4.
Item 5.
Item 6.
Item 7.
CONSONANCE CAPITAL MANAGEMENT LP
By:
Consonance Capman GP LLC, its general partner
By:
/s/ Mitchell Blutt
Mitchell Blutt
Manager and Member
CONSONANCE LIFE SCIENCES, LLC
By:
/s/ Kevin Livingston
Kevin Livingston
Manager
CONSONANCE CAPMAN GP, LLC
By:
/s/ Mitchell Blutt
Mitchell Blutt
Manager and Manager
/s/ Mitchell Blutt
/s/ Benny Soffer
Benny Soffer
/s/ Kevin Livingston
Kevin Livingston
1 Year Consonance HFW Acquisition Chart |
1 Month Consonance HFW Acquisition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions